Navigation Links
Beth Israel Medical Center Receives Major American Cancer Society Grant Toward Improving Pain Management in Chinese Cancer Patients
Date:6/22/2009

$1.76 Million Grant from the American Cancer Society to Hospital's Nationally Recognized Department of Pain Medicine and Palliative Care and Asian Services Center

NEW YORK, June 22 /PRNewswire/ -- Beth Israel Medical Center's nationally recognized Department of Pain Medicine and Palliative Care and the Asian Services Center has received a $1.76 million grant from the American Cancer Society (ACS) to study the best ways to improve pain management in community-dwelling Chinese cancer patients in New York City. The grant announces a partnership with the department, the Asian Services Center, and community oncologists to create and test a highly innovative model of rapid quality improvement in an economically disadvantaged community of largely first and second generation Chinese Americans.

"This grant allows us to examine a method to improve health care access and the practice capacity of community oncologists to deliver state-of-the-art pain interventions to the growing population of Chinese cancer patients," said Lara Dhingra, Ph.D., study principal investigator and Attending Psychologist in the Department of Pain Medicine and Palliative Care. "There is a major need to develop and distribute best practices strategies to manage cancer pain in real-life settings, especially in underserved communities."

"This is the first known study to bring QI to the large population of Chinese cancer patients," said Tak Kwan, MD, Executive Chief of the Asian Services Center. "The study will develop and test a QI program to improve pain and symptoms among underserved, community-based Chinese American cancer patients, and evaluate factors that influence its uptake and sustainability."

This five-year $1.76 million grant aims to test the effectiveness of a quality improvement (QI) intervention to enhance pain management for underserved ethnic Chinese cancer patients. It will also determine
'/>"/>

SOURCE Beth Israel Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Accumetrics, Inc. Announces Distribution Channels in Israel and Cyprus
2. Herleys Israeli Subsidiary, GMI Eyal, is Selected to Provide Complex Microwave Switch Assemblies for a U.S. Customer
3. Mrs. Lily Safra, President of the Edmond J. Safra Foundation, to Announce Major New Medical Research Initiative During Israel Visit
4. New Hope & Resilience After Destruction and Killings in Gaza, Israel
5. The Department of Pain Medicine and Palliative Care at Beth Israel Medical Center is Named 2009 Center of Excellence Award Winner by the American Pain Society
6. France-Israel scientific cooperation agreement
7. Autism Support Network and the Israeli Society for Autistic Children Form International Alliance
8. Misonix Announces New Distribution Agreement for Israel
9. Female genital mutilation among Israels Negev Bedouins has virtually disappeared -- BGU study
10. Beth Israel Deaconess Urged to Investigate Member of Board of Overseers Who Raised Millions for Madoff
11. Healthcare Data Services (HDS) Announces Contract with Beth Israel Deaconess Physician Organization (BIDPO) and Beth Israel Deaconess Medical Center (BIDMC)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 1Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 2Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 3Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 4ClariVein 28TM 29 Catheter for Varicose Veins 3A Further Clinical Trial Results to Be Presented 5019 1ClariVein 28TM 29 Catheter for Varicose Veins 3A Further Clinical Trial Results to Be Presented 5019 2NewCardio Completes 242 9 Million Private Placement 57625 1NewCardio Completes 242 9 Million Private Placement 57625 2NewCardio Completes 242 9 Million Private Placement 57625 3NewCardio Completes 242 9 Million Private Placement 57625 4